Evidence map›Paper›PMID 41103278›Full record

ArticleJournal of inflammation research2025

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect.

Lei Gu, Jing Lin, Jian Yue, Zeyi Liu, Jian-An Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lei Gu *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Jing Lin *Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.ORCID 0000-0002-6368-6455
Jian Yue *The People's Hospital of Gaozhou, Gaozhou, Guangdong, People's Republic of China.
Zeyi LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Jian-An HuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Janus kinase (JAK) inhibitors, developed for autoimmune diseases, have been repurposed as potential therapies for severe COVID-19. Growing evidence indicates that their clinical utility is heterogeneous and cannot be generalized as a class effect. In this Perspective, we focus on the clinical evidence base for JAK inhibitors in COVID-19 and emphasize baricitinib as the the only agent with consistent mortality benefit and highlights the need for agent-specific recommendations and individualized treatment strategies.

Indexed as

baricitinibCOVID-19immunomodulationjanus kinase inhibitorsruxolitinibtofacitinib

Identifiers

PMID41103278
PMCPMC12523554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.